Develop more effective and safer anti-microbial therapies and advanced diagnostics
Antimicrobial Resistance: An Urgent Threat

- 1.27M: 2019 deaths directly attributable to AMR
- 10M: Annual deaths by 2050 if no action taken
- $13.5B: Amount spent annually to combat AMR
**Candida auris**

“Urgent threat” CDC, March 2023

1-4% of cases resistant to all clinical antifungals

- 63 cases in 2016
- 173 cases in 2017
- 331 cases in 2018
- 478 cases in 2019
- 757 cases in 2020
- 1,474 cases in 2021
- 2,377 cases in 2022

US C. auris cases: 177% CAGR

**Babesiosis**

“Emerging threat” CDC, March 2023

~90% cases undiagnosed

Increasing incidence

Ineffective treatments

Poor diagnostics
Potentiators of Anti-Microbial Susceptibility

Rapid Diagnostic Testing (RDT)

Detect infection before symptoms

Anti-microbial adjuvants
**Therapeutics**

$4M in cumulative non-dilutive funding by 2024
Protected by Yale IP

**Diagnostics**

In negotiations for $2M of funding
Protected by Yale IP

---

**Radical cure for the ID pipeline**
Thank you!

info@curatixbio.com